TCG Crossover (TCGX) is a healthcare and life sciences investment firm dedicated to advancing disruptive medicines. It invests across both private and public markets, focusing on innovative biotech companies building transformative therapies.
40% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-b (50% of deals). Average disclosed round size is $201.2M (across 10 rounds with reported amounts).
Portfolio
8
Fund Size
$1.3B
Top Stage
Series B
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Corxel | Series D | $287M | Sep 2026 |
| CCorxel Pharmaceuticals Limited | Series D | $287M | Jan 2026 |
| Corxel | Series D | $287M | Jan 2026 |
 Vicebio | Series B | $100M | Sep 2024 |
 Arbor Biotechnologies | Series B | $215M | Nov 2021 |
 Entrada | Series B | $116M | Jan 2021 |
| AArbor Biotechnologies | Series B | $215M | Jan 2021 |
 RayzeBio | Series C | $108M | Jan 2021 |
| CCorxel Pharmaceuticals Limited | Unknown | $287M | — |
| AAffinia Therapeutics | Series B | $110M | — |
Top Co-Investors
RA Capital Management5 shared
SR One4 shared
SymBiosis4 shared
HBM Healthcare Investments4 shared
Logos Capital3 shared
The Goldman Sachs Group, Inc.2 shared
Redmile Group2 shared
Adage Capital Management2 shared
The Invus Group, LLC2 shared
Tao Capital Partners2 shared
Illumina Ventures2 shared
Tekla Capital Management2 shared
T. Rowe Price2 shared
Section 322 shared
Surveyor Capital2 shared
Deep Track Capital2 shared
ARCH Venture Partners2 shared
Ono Venture Investment2 shared
Vertex Pharmaceuticals2 shared
Last updated: 19 September 2026